Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Michael's Hospital
mi
from
Stevens Point, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Diagnostic and Treatment Center
mi
from
Weston, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Diagnostic and Treatment Center
mi
from
Weston, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Status: Enrolling
Updated:  3/21/2018
Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Status: Enrolling
Updated: 3/21/2018
Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
A Prospective Feasibility and Cost Analysis of Peripheral Blood Stem Cell Mobilization Using Pegfilgrastim in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  3/22/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
A Prospective Feasibility and Cost Analysis of Peripheral Blood Stem Cell Mobilization Using Pegfilgrastim in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 3/22/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Enrolling
Updated:  3/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Enrolling
Updated: 3/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Status: Enrolling
Updated:  3/23/2018
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Status: Enrolling
Updated: 3/23/2018
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
The Mayo Clinic
mi
from
Rochester, MN
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
Rigshospitalet University Hospital
mi
from
Copenhagen,
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
Rigshospitalet University Hospital
mi
from
Copenhagen,
Click here to add this to my saved trials
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Status: Enrolling
Updated:  3/26/2018
Massachusetts General Hospital
mi
from
Boston, MA
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Status: Enrolling
Updated: 3/26/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Mayo Clinic Scottsdale Recruiting
mi
from
Scottsdale, AZ
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Mayo Clinic Scottsdale Recruiting
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
UC San Diego Moores Cancer Center
mi
from
San Diego, CA
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
UC San Diego Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Northwestern University
mi
from
Chicago, IL
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
University of Chicago
mi
from
Chicago, IL
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
University of Michigan
mi
from
Ann Arbor, MI
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Weill-Cornell Medical College
mi
from
New York, NY
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
MD Anderson Cancer Center, Department of Leukemia
mi
from
Houston, TX
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
MD Anderson Cancer Center, Department of Leukemia
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia
Status: Enrolling
Updated:  3/28/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia
Status: Enrolling
Updated: 3/28/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated:  3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated: 3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated:  3/28/2018
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated: 3/28/2018
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Hazard, KY
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Hazard, KY
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Rochester, MN
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Rochester, NY
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Boston, MA
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
mi
from
Camperdown,
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
mi
from
Camperdown,
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Phase II Study of 5-azacytidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/29/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Phase II Study of 5-azacytidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/29/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy
Efficacy of a Novel, High-Sensitivity, Portable, Hand-Held Gamma Camera Used Intraoperatively for Identification of Sentinel Lymph Nodes With Lymphoscintigraphy
Status: Enrolling
Updated:  3/29/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy
Efficacy of a Novel, High-Sensitivity, Portable, Hand-Held Gamma Camera Used Intraoperatively for Identification of Sentinel Lymph Nodes With Lymphoscintigraphy
Status: Enrolling
Updated: 3/29/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated:  3/30/2018
Clinical Research Facility
mi
from
Boston, MA
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated: 3/30/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated:  3/30/2018
mi
from
Copenhagen Ø,
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated: 3/30/2018
mi
from
Copenhagen Ø,
Click here to add this to my saved trials
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/30/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/30/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT
Status: Enrolling
Updated:  3/30/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT
Status: Enrolling
Updated: 3/30/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/2/2018
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/2/2018
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  4/2/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 4/2/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Status: Enrolling
Updated:  4/3/2018
Medical University of South Carolina
mi
from
Charleston, SC
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Status: Enrolling
Updated: 4/3/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Mount Sinai Hospital
mi
from
New York, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Hôpital St. Louis
mi
from
Paris,
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Hôpital St. Louis
mi
from
Paris,
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
White Plains Hospital Center for Cancer Care
mi
from
White Plains, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
White Plains Hospital Center for Cancer Care
mi
from
White Plains, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Saint Louis University
mi
from
Saint Louis, MO
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
City of Hope
mi
from
Duarte, CA
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials